Filtered By:
Condition: Heart Failure
Education: Study
Therapy: Corticosteroid Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 25 results found since Jan 2013.

Long-acting bronchodilator initiation in COPD and the risk of adverse cardio-pulmonary events: A population-based comparative safety study.
CONCLUSION: COPD treatment initiation with tiotropium compared with LABA does not increase cardiovascular risk in the first year of treatment. The risk of pneumonia is higher with LABA, a likely effect of the inhaled corticosteroids present in many LABA inhalers used in real world clinical practice. PMID: 27554300 [PubMed - as supplied by publisher]
Source: Chest - August 19, 2016 Category: Respiratory Medicine Authors: Suissa S, Dellaniello S, Ernst P Tags: Chest Source Type: research

Long-acting bronchodilator initiation in COPD and cardio-pulmonary risks: A population-based comparative effectiveness study
Long-acting bronchodilators, including long-acting beta2-agonists (LABA) and the anticholinergic tiotropium, are recommended as initial maintenance treatment in COPD, though their risk on cardio-pulmonary events remains uncertain in real world settings. We assessed whether treatment initiation with tiotropium increases the risk of acute myocardial infarction (AMI), stroke, heart failure, arrhythmia and pneumonia, relative to a LABA.We identified all new users of a long-acting bronchodilator during 2002-2012, age 55 or older, from the United Kingdom's Clinical Practice Research Datalink. Each patient who initiated tiotropiu...
Source: European Respiratory Journal - November 7, 2016 Category: Respiratory Medicine Authors: Suissa, S., Dell'Aniello, S., Ernst, P. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research

Controversial cardiovascular and hematologic comorbidities in atopic dermatitis
AbstractAtopic dermatitis ’ (AD) systemic involvement is wide-reaching. The cardiovascular and hematological comorbidities of AD have potential for considerable economic and physical burden; however, data surrounding the association between these comorbidities and AD is controversial. This review discusses the cardiovascul ar and hematological comorbidities of AD, detailing the conflicting evidence, pathophysiology, and connection to medications. A PubMed search was conducted for studies detailing the association of cardiovascular and hematological comorbidities with AD, providing approximately 30 results. Additional sea...
Source: Archives of Dermatological Research - May 10, 2021 Category: Dermatology Source Type: research

Chronic obstructive pulmonary disease.
Abstract The global prevalence of physiologically defined chronic obstructive pulmonary disease (COPD) in adults aged >40 yr is approximately 9-10 per cent. Recently, the Indian Study on Epidemiology of Asthma, Respiratory Symptoms and Chronic Bronchitis in Adults had shown that the overall prevalence of chronic bronchitis in adults >35 yr is 3.49 per cent. The development of COPD is multifactorial and the risk factors of COPD include genetic and environmental factors. Pathological changes in COPD are observed in central airways, small airways and alveolar space. The proposed pathogenesis of COPD includes pr...
Source: The Indian Journal of Medical Research - February 1, 2013 Category: Biomedical Science Authors: Vijayan VK Tags: Indian J Med Res Source Type: research

Mortality of bullous pemphigoid in Singapore: risk factors and causes of death in 359 patients seen at the National Skin Centre
ConclusionThis study confirmed an increased 3‐year mortality rate for BP patients in Singapore. Risk factors for increased mortality include medical co‐morbidities, especially neurological, cardiac and renal diseases. Treatment with combination therapy, including the use of low to moderate dose corticosteroid, appeared to decrease mortality risk in BP patients.This article is protected by copyright. All rights reserved.
Source: British Journal of Dermatology - December 1, 2013 Category: Dermatology Authors: S.C.S. Cai, J.C. Allen, Y.L. Lim, S.H. Chua, S.H. Tan, M.B.Y. Tang Tags: Original Article Source Type: research

Mortality of bullous pemphigoid in Singapore: risk factors and causes of death in 359 patients seen at the National Skin Centre.
CONCLUSION: This study confirmed an increased 3-year mortality rate for BP patients in Singapore. Risk factors for increased mortality include medical co-morbidities, especially neurological, cardiac and renal diseases. Treatment with combination therapy, including the use of low to moderate dose corticosteroid, appeared to decrease mortality risk in BP patients. This article is protected by copyright. All rights reserved. PMID: 24372558 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - December 24, 2013 Category: Dermatology Authors: Cai SC, Allen JC, Lim YL, Chua SH, Tan SH, Tang MB Tags: Br J Dermatol Source Type: research

Summary: International Kidney Cancer Symposium
Conclusions:  Ideal ischemia time is 20-25 minutes or less improves short and long term renal function.  >25 minutes carried 5 year risk of new onset stage 4 CKD No differences on GFR for cold vs. warm ischemia times Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR.  No ischemia preserves renal function better than warm. Longer cold ischemia times were equivalent to shorter warm ischemia times. Quality and quantity of the remaining kidney is associated with ultimate renal function. Robotics in RCC Surgery Gennady Bratslavsky, MD The...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news

Lupus Damage and Waist Circumference as the Independent Risk Factors for Cardiovascular Disease in SLE Patients from Phramongkutklao Hospital.
CONCLUSION: Lupus damage, waist circumference more than 90 centimeters in male or more than 80 centimeters in female were the independent risk factors for CVD in SLE patients. PMID: 27276740 [PubMed - in process]
Source: Journal of the Medical Association of Thailand = Chotmaihet thangphaet - June 11, 2016 Category: Journals (General) Tags: J Med Assoc Thai Source Type: research

Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β2-Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid.
CONCLUSIONS: Despite concerns about the CCV effects of LAMA and LABA monotherapy, the LABA/LAMA combination had similar or lower risk of these events in comparison to LABA/ICS. Further studies are recommended to confirm these findings. PMID: 28677404 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - July 1, 2017 Category: Drugs & Pharmacology Authors: Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA Tags: Ann Pharmacother Source Type: research

Summary: International Kidney Cancer Symposium
Conclusions:  Ideal ischemia time is 20-25 minutes or less improves short and long term renal function. >25 minutes carried 5 year risk of new onset stage 4 CKD No differences on GFR for cold vs. warm ischemia times Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR.  No ischemia preserves renal function better than warm. Longer cold ischemia times were equivalent to shorter warm ischemia times. Quality and quantity of the remaining kidney is associated with ultimate renal function. Robotics in RCC Surgery Gennady Bratslavsky, MD The opening question ...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news